Three cases of severe drug-induced liver injury caused by abiraterone acetate in advanced metastatic prostate cancer
The Showa Medical University Journal · 2025
DOI: 10.15369/smuj.37.3_141 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Showa Medical University Journal, 2025. Verfasst von Yoshihiro Nakagami und 9 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
Abiraterone acetate is used to treat high-risk hormone-sensitive prostate cancer and metastatic castration-resistant prostate cancer.However, drug-induced liver injury is a complication of abiraterone acetate administration.Drug-induced liver injury can be categorized as hepatocellular, cholestatic, or mixed type based on the R ratio derived from the ratio of alanine aminotransferase to alkaline phosphatase.Case 1 : An 87-year-old man experienced liver injury caused by abiraterone acetate treatment of metastatic hormone-sensitive prostate cancer.Grade 4 aspartate aminotransferase and alanine aminotransferase increasing were observed for 6 weeks after treatment.The R ratio was 27.5 ; therefore, the drug-induced liver injury was diagnosed as the hepatocellular type.Case 2 : A 66-year-old man experienced liver injury caused by abiraterone acetate treatment of metastatic castration-resistant prostate cancer.Four weeks after treatment, Grade 3 aspartate aminotransferase, Grade 4 alanine aminotransferase, and Grade 3 γ-glutamyl transpeptidase increasing were observed.The R ratio was 7.0 ; therefore, the drug-induced liver injury was diagnosed as the hepatocellular type.Case 3 : A 74-year-old man experienced liver injury caused by abiraterone acetate treatment of metastatic hormone-sensitive prostate cancer.Four weeks after treatment, Grade 3γ-glutamyl transpeptidase and Grade 3 alkaline phosphatase increasing were observed.The R ratio was 0.4 ; thus, the drug-induced liver injury was diagnosed as cholestatic type.Severe drug-induced liver injury is a potential complication of abiraterone acetate therapy.Monitoring of liver function is recommended at least every 2 weeks for the first 3 months of treatment.
Zitieren
APA
Nakagami, Y., Mugita, T., Doguchi, A., Kurokawa, M., Okada, S., Inoue, T., Omizu, M., Oshinomi, K., Nagata, M., & Fukagai, T. (2025). Three cases of severe drug-induced liver injury caused by abiraterone acetate in advanced metastatic prostate cancer. The Showa Medical University Journal. https://doi.org/10.15369/smuj.37.3_141
Vancouver
Nakagami Y, Mugita T, Doguchi A, Kurokawa M, Okada S, Inoue T, et al. Three cases of severe drug-induced liver injury caused by abiraterone acetate in advanced metastatic prostate cancer. The Showa Medical University Journal. 2025. doi:10.15369/smuj.37.3_141
BibTeX
@article{Nakagami2025,
author = {Nakagami, Yoshihiro and Mugita, Toshiki and Doguchi, Ayana and Kurokawa, Masahiro and Okada, Sho and Inoue, Tatsuki and Omizu, Madoka and Oshinomi, Kazuhiko and Nagata, Masakazu and Fukagai, Takashi},
title = {Three cases of severe drug-induced liver injury caused by abiraterone acetate in advanced metastatic prostate cancer},
journal = {The Showa Medical University Journal},
year = {2025},
doi = {10.15369/smuj.37.3_141}
}
EUVIMED